Ligand Pharmaceuticals Incorporated (LGND) Q2 2016 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.55%

Ligand Pharmaceuticals reported a strong EPS performance, exceeding expectations significantly. However, the stock reacted negatively, declining by 0.55%. Investors may be concerned about the lack of revenue data and guidance, which could indicate uncertainty about future growth prospects.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.50	N/A	+127.27%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed cautious optimism about the company's future, focusing on the positive EPS surprise. They did not provide specific revenue guidance.

Management highlighted the strong performance in EPS despite the lack of revenue guidance.

They emphasized ongoing efforts to enhance product pipeline and partnerships.

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.55%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.55%

Key numbers

Management commentary